Prof. Shidong Xu 徐世东
Chief Physician, Professor
Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of small pulmonary nodules, lung cancer, and mediastinal tumors. Specializes in minimally invasive techniques including thoracoscopy, mediastinoscopy, and da Vinci robotic surgery.
Dr. Xu is a Professor and former Director of Thoracic Surgery at Harbin Medical University Cancer Hospital. Dr. Xu earned an MD from Harbin Medical University in 2005, following earlier degrees in 1988. Training includes fellowships at the Cancer Hospital of the Chinese Academy of Medical Sciences (1992) and UPMC (2008), with visits to UCSF (2005) and Singapore Central Hospital (2006).
Professional roles
- Chair, Thoracic Surgery Branch, Heilongjiang Medical Promotion Association
- Chair, Lung Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Standing Committee Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Thoracic Surgery Professional Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Xu Shidong). Papers usually list the name as Shidong Xu or Xu S.
Selected publications
61 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Respir Res, 2026 (senior author): Mechanism study of RUNX1/NSUN2 upregulating fatty acid-binding protein 5 through 5-methylcytosine methylation to mediate lipid metabolic reprogramming to promote immunotherapy resistance in non-small cell lung cancer. PubMed 42231351
- Transl Lung Cancer Res, 2026 (senior author): Efficacy and mechanisms of cisplatin and sulforaphane nanoparticles in alleviating cisplatin resistance in non-small cell lung cancer. PubMed 41659256
- Oncol Rep, 2025 (senior author): RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125. PubMed 40341413
- Invest New Drugs, 2025 (senior author): Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition. PubMed 40404898
- Am J Cancer Res, 2025 (senior author): FTO-mediated m6A modification of QPCT promotes tumorigenesis in lung adenocarcinoma by inducing macrophage chemotaxis and M2 polarization. PubMed 40226457
- J Cardiothorac Surg, 2024 (senior author): Safety of one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after uniportal video-assisted thoracoscopic surgery pneumonectomy. PubMed 39026246
- Clin Respir J, 2023 (senior author): microRNA-651-5p affects the proliferation, migration, and invasion of lung cancer cells by regulating Calmodulin 2 expression. PubMed 37470336
- Medicina (Kaunas), 2023 (senior author): Predictive Value of Gene Databases in Discovering New Biomarkers and New Therapeutic Targets in Lung Cancer. PubMed 36984548
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion